Literature DB >> 28252164

Inhibition of invasion and migration of prostate cancer cells by miRNA-509-5p via targeting MDM2.

X M Tian1, Y Z Luo2, P He2, J Li2, Z W Ma2, Y An3.   

Abstract

Prostate cancer is a common malignancy of the male reproductive-urinary system. MDM2 is an oncogene, whose expression can be regulated by microRNA (miRNA). The present study investigated the expression and correlation of miRNA-509-5p and MDM2 to determine the mechanism of their function in invasion and migration of prostate cancer cells. RT-PCR was performed to detect the expression of miRNA-509-5p and MDM2 in tumor, tumor-adjacent, and normal tissues, obtained from prostate cancer patients, using the HGC-27 cell line as an in vitro model. Cultured HGC-27 cells were transfected with miRNA-509-5p mimics, miRNA-509-5p inhibitor, and mimic control. Expression levels of miRNA-509-5p and MDM2 were quantified by RT-PCR. Cell proliferation and invasion/migration were examined by the MTT and transwell assays, respectively. MiRNA-509-5p was significantly down-regulated in prostate cancer cells exhibiting high MDM2 mRNA levels. MiRNA mimic transfection elevated miRNA levels and suppressed MDM2 expression. With prolonged incubation time, the proliferation ratio and OD values of miRNA-509-5p mimic transfected cells decreased, along with decrease in cell migration and invasion. These results suggested that miRNA-509-5p negatively regulates MDM2 expression via targeting the 3'-UTR of genes. As a novel tumor suppressor, miRNA-509-5p in prostate cancer HGC-27 cells can suppress MDM2 expression and inhibit cell proliferation, invasion, and migration. Therefore, miRNA-509-5p could be used as a novel therapeutic agent in the treatment of prostate cancer.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28252164     DOI: 10.4238/gmr16019195

Source DB:  PubMed          Journal:  Genet Mol Res        ISSN: 1676-5680


  7 in total

1.  lncRNA MNX1‑AS1 promotes prostate cancer progression through regulating miR‑2113/MDM2 axis.

Authors:  Dong Liang; Chuanjie Tian; Xiaowen Zhang
Journal:  Mol Med Rep       Date:  2022-05-26       Impact factor: 3.423

Review 2.  The potential of microRNAs as human prostate cancer biomarkers: A meta-analysis of related studies.

Authors:  Chun-Jiao Song; Huan Chen; Li-Zhong Chen; Guo-Mei Ru; Jian-Jun Guo; Qian-Nan Ding
Journal:  J Cell Biochem       Date:  2017-12-04       Impact factor: 4.429

3.  Downregulation of miR‑224‑5p in prostate cancer and its relevant molecular mechanism via TCGA, GEO database and in silico analyses.

Authors:  Bin-Liang Gan; Li-Jie Zhang; Li Gao; Fu-Chao Ma; Rong-Quan He; Gang Chen; Jie Ma; Jin-Cai Zhong; Xiao-Hua Hu
Journal:  Oncol Rep       Date:  2018-10-03       Impact factor: 3.906

Review 4.  Enhanced Inhibition of Tumorigenesis Using Combinations of miRNA-Targeted Therapeutics.

Authors:  Svetlana Miroshnichenko; Olga Patutina
Journal:  Front Pharmacol       Date:  2019-05-16       Impact factor: 5.988

5.  miR-1305 Inhibits The Progression Of Non-Small Cell Lung Cancer By Regulating MDM2.

Authors:  Yuxing Cai; Yi Hao; HaiFeng Ren; ZhiGuo Dang; Hui Xu; Xiangfei Xue; Yan Gao
Journal:  Cancer Manag Res       Date:  2019-11-11       Impact factor: 3.989

6.  Fibronectin Modulates the Expression of miRNAs in Prostate Cancer Cell Lines.

Authors:  Bruno Martinucci; Maira Smaniotto Cucielo; Brenda Carvalho Minatel; Sarah Santiloni Cury; Gabriel Henrique Caxali; Mirian Carolini Esgoti Aal; Sergio Luis Felisbino; Danillo Pinhal; Robson Francisco Carvalho; Flávia Karina Delella
Journal:  Front Vet Sci       Date:  2022-07-11

7.  TUG1 promotes retinoblastoma progression by sponging miR-516b-5p to upregulate H6PD expression.

Authors:  Caimei Xiu; Ruiying Song; Jing Jiang
Journal:  Transl Cancer Res       Date:  2021-02       Impact factor: 1.241

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.